Caitlin Elgarten, MD, MSCE

female silhouette icon
Caitlin Elgarten, MD, MSCE, is an attending physician with the Cancer Center at Children's Hospital of Philadelphia.

Locations: Main Hospital

Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467)

Education and Training

Medical School

MD - Columbia University, New York, NY


Pediatrics - The Children's Hospital of Philadelphia, Philadelphia, PA


Pediatrics - The Children's Hospital of Philadelphia, Philadelphia, PA


Pediatric Hematology/Oncology - The Children's Hospital of Philadelphia, Philadelphia, PA
Pharmacoepidemiology - University of Pennsylvania School of Medicine, Philadelphia, PA

Board Certification

Pediatric Hematology-Oncology – American Board of Pediatrics
Pediatrics – American Board of Pediatrics

Graduate Degree

MSCE - University of Pennsylvania, Philadelphia, PA

Titles and Academic Titles

Attending Physician

Assistant Professor, Perelman School of Medicine at the University of Pennsylvania

Departments and Services




Elgarten C: Absolute Lymphocyte Count Recovery Following Initial AML Therapy, Implications for Adoptive Cell Therapy. Pediatric Blood & Cancer (accepted) 2022.

Elgarten CW, Otto WR, Shenton L, Stein MT, Horowitz J, Aftandilian C, Arnold SD, Bona KO, Caywood E, Collier AB, Gramatges MM, Henry M, Lotterman C, Maloney K, Modi AJ, Mian A, Mody R, Morgan E, Raetz EA, Verma A, Winick N, Wilkes JJ, Yu JC, Aplenc R, Fisher BT, Getz KD.: Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia. Infect Control Hosp Epidemiol Apr 2022.

Elgarten CW, Thompson JC, Angiolillo A, Chen Z, Conway S, Devidas M, Gupta S, Kairalla JA, McNeer JL, O'Brien MM, Rabin KR, Rau RE, Rheingold SR, Wang C, Wood C, Raetz EA, Loh ML, Alexander S, Miller TP.: Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer 2022.


Elgarten CW, Li Y, Getz KD, Hemmer M, Huang YV, Hall M, Wang T, Kitko CL,Jagasia MH, Nishihori T, Murthy HS, Hashem H, Cairo MS, Sharma A, Hashmi SK,Askar M, Beitinjaneh A, Kelly MS, Auletta JJ, Badawy SM, Mavers M, Aplenc R,MacMillan ML, Spellman SR, Arora M, Fisher BT: Broad spectrum antibiotics and risk of graft-versus-host disease in pediatric patients transplanted for acute leukemia: association of carbapenem use with risk of acute GVHD. Transplant Cell Ther 27(2): 177.e1-177.e8, Feb 2021 Notes: Epub 2020 Dec 21.

Diorio C, Vardaro J, Wei Y, Mauro J, Croy C, Oranges KE, Reilly AF, Bailey LC, Jubelirer T, Elgarten CW*, Freedman JL.: Improving Guideline-Congruent Care for Chemotherapy-Induced Nausea and Vomiting Prophylaxis in Pediatric Oncology Patients. JCO Oncology Practice 18(3): e412-e419, October 2021.

Elgarten CW, Tanes C, Lee J-j, Danziger-Isakov LA, Grimley MS, Green MD, Michaels MG, Barnum JL, Ardura MI, Auletta JJ, Blumenstock J, Seif AE, Bittinger KL, Fisher BT: Early microbiome and metabolome signatures in pediatric patients undergoingallogeneic hematopoietic cell transplantation. Pediatr Blood Cancer 69(1): e29384, October 2021.

Elgarten CW, Wood AC, Li Y, Alonzo TA, Brodersen LE, Gerbing RB, Getz KD,Huang YV, Loken M, Meshinchi S, Pollard JA, Sung L, Woods WG, Kolb EA, GamisAS, Aplenc R.: Outcomes of intensification of induction chemotherapy for children withhigh-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer 68(12): e29281, October 2021 Notes: Epub ahead of print.

Hayes M, Newman AM, Boge CLK, Galetaki DM, Elgarten CW, Freedman JL, OlsonTS, Fisher BT.: Incidence of CMV Infection and Disease and Adverse Events Associatedwith Antiviral Therapy in a Retrospective Cohort of Allogeneic Hematopoietic Cell Transplant Recipients at an Academic Children's Hospital. J Pediatric Infect Dis Soc. 10(9): 910-918, Jul 2021.

Ibrahimova A, Winestone LE, Miller TP, Kettler K, Seif AE, Huang YS, Elgarten CW, Myers RM, Fisher BT, Aplenc R, Getz KD: Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia. Pediatr Blood Cancer 68(7): e28940, March 2021.

Barz Leahy A, Li Y, Talano JA, Elgarten CW, Seif AE, Wang Y, Johnson B, Monos D, Kadauke S, Olson TS, Freedman JL, Wray L, Grupp SA, Bunin NJ: Unrelated donor α/β T-cell and B-cell-depleted HSCT for the treatment of pediatric acute leukemia. Blood Advances 6(4): 1175-1185, Feb 2021.


Cahen VC, Li Y, Elgarten CW, Dinofia AM, Wilkes JJ, Winestone L, Huang Y-S, Fitzgerald J, Gramatges MM, Rabin KR, Fisher BT, Getz KD, Aplenc R, Seif A.: Identifying relapses & stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: capturing national outcomes irrespective of trial enrollment. Pediatric Blood and Cancer 68(9): e28315, May 2020.


Elgarten CW, Levy EM, Mattei P, Fisher BT, Olson TS, Freedman JL.: Successful treatment of Pulmonary Mucormycosis in Two Pediatric Hematopoietic Cell Transplant Patients. Pediatric Blood and Cancer 2018.

Elgarten CW, Arnold SD, Li Y, Huang Y-S, Riches M, Gerber JS, Aplenc R, Saber W, Fisher BT.: Hospital-level variability in broad-spectrum antibiotic use for children with acute leukemia undergoing hematopoietic cell transplantation.  Infection Control and Hospital Epidemiology 2018.

Elgarten CW, Arnold DE, Bunin NJ, Seif AE. : Outcomes of matched sibling donor bone marrow transplantation in children using single-agent calcineurin inhibitors as prophylaxis for graft versus host disease.  Pediatric Blood Cancer 2018.

Cahen, VC, Li Y, Elgarten CW, DiNofia AM, Wilkes JJ, Winestone LE, Huang Y-S, Fitzgeral JC, Gramatges MM, Rabin KR, Fisher BT, Getz KD, Aplenc R, Seif AE. : Validation of approaches using administrative data to identify relapse and hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia.  Pharmacoepidemiology and Drug Safety 2018.


Elgarten CW, Arnold DE, Bunin NJ, Seif AE. : Outcomes of matched sibling donor bone marrow transplantation in children using single-agent calcineurin inhibitors as prophylaxis for graft versus host disease. Pediatric Blood Cancer 65(2): doi: 10.1002, Jan 2017 Notes: epub.




Freedman JL, Elgarten CW, Rheingold SR: Management of Oncologic Emergencies. Lanzkowsky's Manual of Pediatric Hematology and Oncology 7th edition, June 2021 Notes: Chapter 31, in Lanzkowsky P, Lipton J and Fish J. (Ed.).


Aplenc R, Elgarten CW, Choi JK, Meshinchi S.: Acute Myeloid Leukemia and Myelodysplastic Syndromes. Principles and practice of pediatric oncology 7th edition, 2020 Notes: Chapter 20, in Pizzo P. and Poblack D. (Ed.).

Posters and Presentations


Levy E, Wohlschlaeger A, Atkinson M, Bunin NJ, Elgarten CW, Fisher BT, Grupp SA, Hankins P, Heimall J, Khan R, Metjian T, Olson TS, Roberson H, Freedman JL.: Delivering post-hematopoietic stem cell transplant vaccines in a pediatrician's offices versus specialty care setting. Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR, Virtual 2020 Notes: Poster.


Elgarten CW, Myers RM, Levy EM, Bunin NJ, Freedman JL, Fisher BT, Olson TS.: Cytomegalovirus Reactivation in Children with Hemoglobinopathies who undergo Hematopoietic Cell Transplantation with Distal Alemtuzumab. Transplantation and Cellular Therapy Meetings, Houston, TX 2019 Notes: Poster.

Galetaki D, Hayes M, Newman A, Boge C, Elgarten CW, Freedman JL, Olson TS,Fisher BF.: Retrospective cohort analysis to determine the incidence of CMV infectionand disease in allogeneic hematopoietic cell transplant recipients at an academic children's hospital. IDWeek, Washington DC 2019 Notes: Poster.

Myers RM, Fitzgerald JC, Elgarten CW, Getz KD, Li Y, Hogan J, DiNofia AM,Burrows EK, Aplenc R, Grupp SA, Laskin BL, Maude SL.: Acute Kidney Injury after Chimeric Antigen Receptor T-Cell Therapy for Pediatric Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy Meetings, Houston, TX 2019 Notes: Poster.

Invited Lectures


Elgarten C. "Immunocompromise and Antimicrobials: Or is it the other way around?", Boston Children's Hospital, Pediatric HSCT Development Conference, Boston, Massachucetts. Nov 2021.

Elgarten C. "Anti-infectives after HSCT: Which ones, how much, and what else should we consider?", University of Chicago Medicine, Department of Pediatrics, Chicago, Illinois. Nov 2021.

Elgarten C. "COVID-19 in ALL: Implications for Clinical Trials" - Children's Oncology Group, Cancer Control and Supportive Care, Webinar. Mar 2021.


Elgarten C. "Infant Leukemia"-Newborn Care Network Case Series, Virtual Presentation. May 2020.


Elgarten C. "Early Broad-Spectrum Antibiotics and Risk of Acute Graft-versus-Host Disease in Children". Oral abstract, American Society of Hematology 2019. Orlando, Florida. Dec 2019.

Elgarten C. "Letermovir in Pediatric Transplant" -Children's Oncology Group, Cancer Control and Supportive Care, Atlanta, Georgia. Sept 2019.

Awards and Honors

2021, Top 5 Practice Changing Paper in Transplant-ID
2018, Center for Childhood Cancer Research Translational Scholar in Hematologic Malignancy Award, Children's Hospital of Philadelphia
2010, Paul H. Douglas Fellowship for outstanding work in HIV/AIDS
2010, American Medical Association Seed Grant
2009, Doris Duke Fellowship for Clinical Research

Editorial and Academic Positions

Editorial Positions

2021-present, Ad Hoc Reviewer, Journal of Clinical Oncology
2019-present, Ad Hoc Reviewer, Cancer Medicine
2018-present, Ad Hoc Reviewer, European Journal of Hematology
2018-present, Ad Hoc Reviewer, Journal Pediatric Hematology and Oncology
2017-present, Reviewer, Pediatric Blood and Cancer

Academic and Institutional Committees

2019-present, Co-Lead Physician, Quality Improvement Committee
2018-present, Quality Improvement Committee, Cellular Therapy and Transplant Section
2017-present, Lead Physician, Quality Improvement Committee, Levofloxacin Prophylaxis in Leukemia and Transplant Patients

Leadership and Memberships

Memberships in Professional Organizations


2020-present, Multinational Association for Supportive Care in Cancer
2015-present, Children's Oncology Group
 - 2019-present, Study Committee Member, AALL1731: Children's Oncology Group
 - 2019-present, Study Committee Member, ACCL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL
 - 2018-present, Study Chair, ACCL1932: A Phase 3 Randomized Trial of Letermovir for CMV Prevention in Pediatric Stem Cell Transplant


2017-present, American College of Epidemiology
2016-present, American Society of Pediatric Hematology/Oncology
2016-present, American Society of Hematology
2016-present, American Society of Clinical Oncologists
2016-present, American Society for Blood and Marrow Transplantation